Houston Oncology Summit: MD Anderson's John Heymach, a leading expert in lung cancer, talks about the latest in TKI's, KRAS, Bi-specifics, and more

blonca9
Sep 26, 2024
1 min read

John Heymach gives an overview of how TKIs are progressing in the EGFR and HER2 space, his thoughts on the recent VEGF x PD1 data that has biotech talking, and what to look forward to in KRAS.

Brought to you by:

Recent Posts

See All

RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts

RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy

RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change

Houston Oncology Summit: MD Anderson's John Heymach, a leading expert in lung cancer, talks about the latest in TKI's, KRAS, Bi-specifics, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight